Results 41 to 50 of about 4,898 (191)

In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014−2018 studies in Spain

Journal of Global Antimicrobial Resistance, 2021
: Objectives: The incidence of antimicrobial resistance in Europe is rising. Cefiderocol is approved in Europe for treatment of aerobic Gram-negative bacterial (GNB) infections in adults with limited treatment options. We report the in vitro activity of
Emilia Cercenado, Laura Cardenoso, Rocio Penin, Christopher Longshaw, Anne Santerre Henriksen, Alvaro Pascual   +5 more
doaj   +1 more source

In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains [PDF]

, 2023
: Cefiderocol is a new siderophore cephalosporin that is effective against multidrug-resistant Gram-negative bacteria, including carbapenem-resistant strains.
Bertelli A., Corbellini S., Padovani M., Piccinelli G., De Francesco M. A., Gurrieri F.   +5 more
core   +3 more sources

Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomised controlled trials

Journal of Global Antimicrobial Resistance, 2021
Objectives: The aim of this study was to investigate the clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections. Methods: The PubMed, Embase and Cochrane Library databases as well as the clinical trials registries of ...
Shun-Chung Hsueh, Chien-Ming Chao, Cheng-Yi Wang, Chih-Cheng Lai, Chao-Hsien Chen   +4 more
doaj   +1 more source

Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints [PDF]

, 2023
Background: Cefiderocol is generally active against carbapenem-resistant Klebsiella spp. (CRK) with higher MICs against metallo-beta-lactamase producers. There is a variation in cefiderocol interpretive criteria determined by EUCAST and CLSI.

core   +1 more source

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms

Life, 2023
Antimicrobial resistance continues to increase globally and treatment of difficult-to-treat (DTT) infections, mostly associated with carbapenem-resistant (CR) Pseudomonas aeruginosa, CR Acinetobacter baumannii, and CR- and third-generation-cephalosporins-
Sara Domingues, Tiago Lima, Maria José Saavedra, Gabriela Jorge Da Silva   +3 more
doaj   +1 more source

Development of cefiderocol resistance during treatment in Klebsiella pneumoniae [PDF]

, 2023
International audienceBackgroundCefiderocol, a siderophore-conjugated cephalosporine, is a promising drug used to treat infection with carbapenem-resistant Gram-negative bacteria. Mutations in siderophore receptors are described to confer multiple levels
Marchand, Sandrine, Buyck, Julien, M, Arrivé, François, Deroche, Luc, Martellosio, Jean-Philippe   +4 more
core  

Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study [PDF]

, 2021
International audienceCefiderocol is a novel siderophore cephalosporin, which has proven in vitro activity against carbapenem-resistant (CR) Gram-negative pathogens and stability towards all carbapenemases. The aim of this study was to describe the first
Mihaila, Liliana, Dinh, Aurélien, Clara Duran, Benjamin Wyplosz, Duran, Clara, Tattevin, Pierre, Razazi, Keyvan, Remy Bonnin, Vincent Bunel, Sophie-Caroline Sacleux, Dortet, Laurent, Helga Junot, Dupont, Hervé, Sacleux, Sophie-Caroline, Remy A. Bonnin, Nathalie Grall, Keyvan Razazi, Aurélien Dinh, Wyplosz, Benjamin, S, Bunel, Vincent, Bleibtreu, Alexandre, Laurent Dortet, Pierre Tattevin, Hervé Dupont, Grall, Nathalie, on behalf of the Cefiderocol French Study Group, Junot, Helga, Alexandre Bleibtreu, Bonnin, Rémy, Liliana Mihaila   +29 more
core   +1 more source

Carbapenem- and cefiderocol-resistant Enterobacterales in surface water in Kumasi, Ashanti Region, Ghana [PDF]

Background: MDR pathogens including ESBL- and/or carbapenemase-producing Enterobacterales (ESBL-PE and CPE) increasingly occur worldwide in the One Health context.
Eger, Elias, Adade, Eugene, Knauf, Sascha, Dreyer, Sylvia, Lübcke, Phillip, Homeier-Bachmann, Timo, Heiden, Stefan E., Sylverken, Augustina A, Schaufler, Katharina, Tawiah, Patrick O.   +9 more
core   +1 more source

In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae

Microbiology Spectrum, 2023
Cefiderocol and aztreonam-avibactam (ATM-AVI) both had activity against carbapenem-resistant Gram-negative bacilli, including those that produce metallo-β-lactamases (MBLs).
Yu-Shan Huang, Pao-Yu Chen, Pei-Chun Chou, Jann-Tay Wang   +3 more
doaj   +1 more source

In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany

Pathogens, 2021
In the last two decades, the worldwide dissemination of multidrug-resistant Gram-negative bacteria (MDR-GNB) has continued. Therapy options for such infections caused by MDR-GNB remain scarce, and only few new antimicrobial agents have been granted ...
Beniam Ghebremedhin, Parviz Ahmad-Nejad
doaj   +1 more source